FDA Has No Timeline For PBM Promotion Guidance Reissue
FDA does not have a timeline for reissuance of its draft guidance on promotions by pharmacy benefit management companies.
You may also be interested in...
Pharmacy benefit management companies should not be permitted to control the clinical information delivered via electronic prescribing technology, Pfizer Business Technology Senior Manager Ross Martin told an HHS committee May 27
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011